19.05.2011 • NewsGen-ProbeThermo FisherNovartis

Bidders Emerge For Gen-Probe, Phadia

Bidders emerged for allergy-testing company Phadia and diagnostic test-maker Gen-Probe, according to The Wall Street Journal.

Laboratory equipment company Thermo Fisher Scientific is a leading contender for privately owned Phadia, and is involved in the auction for Gen-Probe, the newspaper reported in its online edition.

Phadia could fetch as much as $3 billion in a sale, while Gen-Probe has a market capitalization of $3.8 billion.

Other bidders for Gen-Probe include Novartis, and Life Technologies Corp, the newspaper said.

Gen-Probe, Phadia, Thermo Fisher declined to comment. Life Technologies and Novartis, which has a partnership with Gen-Probe, could not be immediately reached for comment.

Last month, Gen-Probe hired Morgan Stanley to seek a buyer for the company, sources familiar with the situation said.

 

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.